Open peptide status and evidence data

Peptide evidence,
row by row.

Name: Peptide Local Peptide Evidence and Status Index
Creator: Peptide Local Editorial Desk
Published: 2026-07-24
License: https://peptidelocal.com/data/license

One inspectable index for peptide names, aliases, FDA medicine records, clinical pipeline programs, research-market boards, linked ClinicalTrials.gov records, checked dates, and primary source routes. Categories stay separate so the data remains useful without implying false equivalence.

Coverage is not a clinical score.A source-routing and identity dataset across three different evidence categories. Record count and linked-source count do not measure clinical strength, safety, efficacy, product quality, legal access, or suitability for use.

Coverage by evidence category

Three lanes. Three different questions.

The bars show how many canonical records are published in each category. They do not rank evidence strength or imply that a research listing, clinical program, and approved medicine are interchangeable.

FDA-approved medicines7

Investigational programs13

Research price boards20

Identity to clinical trial connection

Which peptide profiles connect to the current trial snapshot?

Only the 13 tracked investigational programs receive trial counts. Approved-medicine and research-market rows stay blank because this exact-intervention snapshot was not designed to index them. Blank does not mean zero.

13pipeline profiles linked

268unique NCT records

61marked Recruiting

11with posted results

CagrilintideNovo Nordisk52NCT records10 recruiting2 results posted MazdutideInnovent Biologics; licensed from Eli Lilly for China37NCT records10 recruiting1 results posted RetatrutideEli Lilly and Company34NCT records2 recruiting2 results posted SurvodutideBoehringer Ingelheim + Zealand Pharma31NCT records3 recruiting3 results posted CagriSemaNovo Nordisk30NCT records5 recruiting0 results posted MariTideAmgen27NCT records6 recruiting2 results posted ZenagamtideNovo Nordisk24NCT records10 recruiting0 results posted EloralintideEli Lilly and Company19NCT records11 recruiting1 results posted EcnoglutideSciwind Biosciences; Pfizer commercialization partner in Mainland China15NCT records3 recruiting0 results posted PemvidutideAltimmune9NCT records1 recruiting0 results posted PetrelintideZealand Pharma + Roche9NCT records2 recruiting0 results posted EnicepatideRoche / Carmot Therapeutics8NCT records4 recruiting0 results posted VK2735Viking Therapeutics5NCT records0 recruiting0 results posted

How to read this chart: a program can share an NCT record with another program, so the per-program bars should not be summed as unique studies. Registry status is sponsor-submitted and does not establish eligibility, access, approval, or comparative effectiveness.

Open the full clinical trial dataset →

Download the release

Same evidence index. Two formats.

CSVSpreadsheet-ready · 40 recordsDownload ↘JSONMetadata, data dictionary, statistics, and recordsDownload ↘

Search the evidence index

Find the exact name, status, and source record.

Search aliases and sponsor codes, filter by evidence category, inspect current trial linkage, and open the question each row can answer before using it. Linked-record counts measure published coverage only.

Search names, aliases, sponsors, trial linkage, status, or sources

Evidence category

Sort results

40of 40 evidence records shownSource count measures coverage, not clinical strength.

Name and aliases	Evidence category	Current record	How to use this record	Clinical trial snapshot	Checked	Primary source
AOD-9604AOD 9604 · AOD9604 · Tyr-hGH 177-191	US research-market price boardGrowth-signaling analogues	3 of 4 rows in stock5 mg like-for-like comparison5 linked records	Question and boundary This record answers What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access? It does not establish Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	U.S. Food and Drug AdministrationRead the FDA source ↗
BPC-157Body Protection Compound 157 · BPC 157	US research-market price boardTissue and thymic peptides	5 of 7 rows in stock10 mg like-for-like comparison8 linked records	Question and boundary This record answers What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access? It does not establish Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	U.S. Food and Drug AdministrationRead the FDA source ↗
CagrilintideAM833 · NNC0174-0833	Investigational clinical programObesity and metabolic pipeline	Phase 3 monotherapy programNovo Nordisk7 linked records	Question and boundary This record answers Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program? It does not establish Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.	52 matched NCT records10 recruiting · 2 results postedOpen filtered finder →	2026-07-20	ClinicalTrials.govREDEFINE 1 Phase 3 study - NCT05567796 ↗
CagriSemacagrilintide + semaglutide · REDEFINE 1 · REIMAGINE 1-3	Investigational clinical programObesity and metabolic pipeline	Phase 3 / US regulatory reviewNovo Nordisk8 linked records	Question and boundary This record answers Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program? It does not establish Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.	30 matched NCT records5 recruiting · 0 results postedOpen filtered finder →	2026-07-20	ClinicalTrials.govREDEFINE 1 Phase 3 study - NCT05567796 ↗
CJC-1295 DACCJC-1295 with DAC · CJC 1295 DAC · DAC:GRF	US research-market price boardGrowth-signaling analogues	2 of 3 rows in stock5 mg like-for-like comparison4 linked records	Question and boundary This record answers What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access? It does not establish Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	U.S. Food and Drug AdministrationRead the FDA source ↗
CJC-1295 no DACModified GRF 1-29 · Mod GRF 1-29 · CJC 1295 without DAC	US research-market price boardGrowth-signaling analogues	2 of 3 rows in stock5 mg like-for-like comparison4 linked records	Question and boundary This record answers What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access? It does not establish Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	U.S. Food and Drug AdministrationRead the FDA source ↗
DSIPDelta sleep-inducing peptide · Emideltide · DSIP nonapeptide	US research-market price boardNeuropeptides	2 of 3 rows in stock5 mg like-for-like comparison4 linked records	Question and boundary This record answers What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access? It does not establish Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	U.S. Food and Drug AdministrationRead the FDA source ↗
EcnoglutideXW003 · Sciwind ecnoglutide · cAMP-biased GLP-1 receptor agonist · 埃诺格鲁肽	Investigational clinical programObesity and metabolic pipeline	China approvals active; indication-expansion studies continueSciwind Biosciences; Pfizer commercialization partner in Mainland China8 linked records	Question and boundary This record answers Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program? It does not establish Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.	15 matched NCT records3 recruiting · 0 results postedOpen filtered finder →	2026-07-18	ClinicalTrials.govSLIMMER Phase 3 study - NCT05813795 ↗
EGRIFTA WR (Tesamorelin)tesamorelin · Egrifta WR · Egrifta SV · TH9507	FDA-approved medicineFDA-approved GHRF-analog medicine	BLA 022505 · FDA-approved prescription drugTheratechnologies Inc.2 linked records	Question and boundary This record answers Which exact product, application, label company, route, and regulatory record did FDA approve? It does not establish Approval applies to the exact medicine and label record. It does not transfer to compounded products, research listings, or similarly named materials, and it does not determine individual suitability.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	National Library of Medicine, DailyMedCurrent EGRIFTA WR prescribing information ↗
EloralintideLY3841136 · eloralintide peptide · selective amylin receptor agonist	Investigational clinical programObesity and metabolic pipeline	Phase 3 ENLIGHTEN program recruitingEli Lilly and Company9 linked records	Question and boundary This record answers Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program? It does not establish Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.	19 matched NCT records11 recruiting · 1 results postedOpen filtered finder →	2026-07-22	ClinicalTrials.govEloralintide Phase 2 study - NCT06230523 ↗
EnicepatideCT-388 · RO7795068 · RG6640	Investigational clinical programObesity and metabolic pipeline	Phase 3 ENITH program recruitingRoche / Carmot Therapeutics6 linked records	Question and boundary This record answers Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program? It does not establish Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.	8 matched NCT records4 recruiting · 0 results postedOpen filtered finder →	2026-07-18	ClinicalTrials.govCT388-103 Phase 2 study - NCT06525935 ↗
FOUNDAYO (Orforglipron)orforglipron · Foundayo · LY3502970 · NDA 220934	FDA-approved medicineFDA-approved non-peptide GLP-1 comparator	NDA 220934 · FDA-approved prescription drugLilly USA, LLC6 linked records	Question and boundary This record answers Which exact product, application, label company, route, and regulatory record did FDA approve? It does not establish Approval applies to the exact medicine and label record. It does not transfer to compounded products, research listings, or similarly named materials, and it does not determine individual suitability.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-20	National Library of Medicine, DailyMedCurrent FOUNDAYO prescribing information ↗
GHK-CuCopper tripeptide · GHK Cu · Copper tripeptide-1 · Prezatide copper	US research-market price boardCopper and short peptides	3 of 5 rows in stock100 mg like-for-like comparison6 linked records	Question and boundary This record answers What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access? It does not establish Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	National Library of Medicine, PubChemRead the PubChem compound record ↗
IGF-1 LR3Long R3 IGF-1 · Insulin-like growth factor long chain R3 · 100 mcg IGF-1 LR3	US research-market price boardGrowth-signaling analogues	1 of 3 rows in stock0.1 mg like-for-like comparison4 linked records	Question and boundary This record answers What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access? It does not establish Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	National Library of Medicine, PubChemRead the PubChem substance record ↗
IpamorelinNNC 26-0161 · growth hormone secretagogue	US research-market price boardGrowth-signaling analogues	3 of 3 rows in stock10 mg like-for-like comparison4 linked records	Question and boundary This record answers What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access? It does not establish Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	U.S. Food and Drug AdministrationRead the FDA source ↗
Kisspeptin-10Kisspeptin 10 · Kp-10 · Metastin fragment · KISS1 decapeptide	US research-market price boardReproductive-signaling peptides	2 of 3 rows in stock10 mg like-for-like comparison4 linked records	Question and boundary This record answers What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access? It does not establish Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	National Library of Medicine, PubChemRead the PubChem compound record ↗
MariTidemaridebart cafraglutide · AMG 133	Investigational clinical programObesity and metabolic pipeline	Phase 3 program activeAmgen4 linked records	Question and boundary This record answers Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program? It does not establish Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.	27 matched NCT records6 recruiting · 2 results postedOpen filtered finder →	2026-07-20	ClinicalTrials.govPhase 2 dose-ranging study - NCT05669599 ↗
MazdutideIBI362 · LY3305677 · GLP-1/glucagon dual agonist	Investigational clinical programObesity and metabolic pipeline	China approvals active; Phase 3 and indication-expansion studies continueInnovent Biologics; licensed from Eli Lilly for China10 linked records	Question and boundary This record answers Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program? It does not establish Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.	37 matched NCT records10 recruiting · 1 results postedOpen filtered finder →	2026-07-22	ClinicalTrials.govGLORY-1 Phase 3 study - NCT05607680 ↗
Melanotan IMT-I · MT1 · Afamelanotide · Melanotan 1	US research-market price boardMelanocortin analogues	2 of 3 rows in stock10 mg like-for-like comparison4 linked records	Question and boundary This record answers What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access? It does not establish Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	National Library of Medicine, DailyMedRead the current SCENESSE label ↗
Melanotan IIMT-II · MT2 · Melanotan 2	US research-market price boardMelanocortin analogues	1 of 3 rows in stock10 mg like-for-like comparison4 linked records	Question and boundary This record answers What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access? It does not establish Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	U.S. Food and Drug AdministrationRead the FDA source ↗
MOTS-cMOTS c · Mitochondrial open reading frame peptide	US research-market price boardMitochondrial and metabolic	5 of 7 rows in stock10 mg like-for-like comparison8 linked records	Question and boundary This record answers What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access? It does not establish Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	U.S. Food and Drug AdministrationRead the FDA source ↗
NAD+Nicotinamide adenine dinucleotide · NAD plus	US research-market price boardMitochondrial and metabolic	3 of 4 rows in stock1000 mg like-for-like comparison5 linked records	Question and boundary This record answers What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access? It does not establish Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	National Library of Medicine, PubChemRead the PubChem compound record ↗
PemvidutideALT-801 · balanced GLP-1/glucagon dual agonist · Altimmune pemvidutide	Investigational clinical programObesity and metabolic pipeline	Phase 2 programs active; MASH Phase 3 plannedAltimmune9 linked records	Question and boundary This record answers Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program? It does not establish Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.	9 matched NCT records1 recruiting · 0 results postedOpen filtered finder →	2026-07-18	ClinicalTrials.govIMPACT Phase 2b MASH study - NCT05989711 ↗
PetrelintideZP8396 · long-acting amylin analogue	Investigational clinical programObesity and metabolic pipeline	Phase 3 planned; Phase 2 program activeZealand Pharma + Roche5 linked records	Question and boundary This record answers Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program? It does not establish Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.	9 matched NCT records2 recruiting · 0 results postedOpen filtered finder →	2026-07-17	ClinicalTrials.govZUPREME-1 Phase 2 study - NCT06662539 ↗
PT-141 (Bremelanotide)PT 141 · Bremelanotide · Vyleesi	US research-market price boardMelanocortin analogues	2 of 3 rows in stock10 mg like-for-like comparison4 linked records	Question and boundary This record answers What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access? It does not establish Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	National Library of Medicine, DailyMedRead the current DailyMed drug label ↗
RetatrutideLY3437943 · triple agonist · reta · reta peptide	Investigational clinical programObesity and metabolic pipeline	Phase 3 program reporting resultsEli Lilly and Company4 linked records	Question and boundary This record answers Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program? It does not establish Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.	34 matched NCT records2 recruiting · 2 results postedOpen filtered finder →	2026-07-20	ClinicalTrials.govTRIUMPH-1 Phase 3 study - NCT05929066 ↗
SAXENDA (Liraglutide)liraglutide · Saxenda · NN2211 · NDA 206321	FDA-approved medicineFDA-approved incretin medicine	NDA 206321 · FDA-approved prescription drugNovo Nordisk Inc.2 linked records	Question and boundary This record answers Which exact product, application, label company, route, and regulatory record did FDA approve? It does not establish Approval applies to the exact medicine and label record. It does not transfer to compounded products, research listings, or similarly named materials, and it does not determine individual suitability.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	National Library of Medicine, DailyMedCurrent SAXENDA prescribing information ↗
SCENESSE (Afamelanotide)afamelanotide · Scenesse · CUV1647 · NDA 210797	FDA-approved medicineFDA-approved melanocortin medicine	NDA 210797 · FDA-approved prescription drugCLINUVEL INC.2 linked records	Question and boundary This record answers Which exact product, application, label company, route, and regulatory record did FDA approve? It does not establish Approval applies to the exact medicine and label record. It does not transfer to compounded products, research listings, or similarly named materials, and it does not determine individual suitability.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	National Library of Medicine, DailyMedCurrent SCENESSE prescribing information ↗
SelankTP-7 · selank acetate	US research-market price boardNeuropeptides	2 of 3 rows in stock10 mg like-for-like comparison4 linked records	Question and boundary This record answers What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access? It does not establish Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	U.S. Food and Drug AdministrationRead the FDA source ↗
SemaxACTH(4-7)-PGP · MEHFPGP · Semax heptapeptide	US research-market price boardNeuropeptides	3 of 3 rows in stock10 mg like-for-like comparison4 linked records	Question and boundary This record answers What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access? It does not establish Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	U.S. Food and Drug AdministrationRead the FDA source ↗
SermorelinGHRH 1-29 · Sermorelin acetate · Geref	US research-market price boardGrowth-signaling analogues	2 of 3 rows in stock5 mg like-for-like comparison4 linked records	Question and boundary This record answers What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access? It does not establish Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	U.S. Food and Drug AdministrationRead the FDA orphan-drug record ↗
SurvodutideBI 456906 · glucagon/GLP-1 dual agonist	Investigational clinical programObesity and metabolic pipeline	Phase 3 program active and reportingBoehringer Ingelheim + Zealand Pharma7 linked records	Question and boundary This record answers Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program? It does not establish Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.	31 matched NCT records3 recruiting · 3 results postedOpen filtered finder →	2026-07-20	ClinicalTrials.govSYNCHRONIZE-1 Phase 3 study - NCT06066515 ↗
TB-500Thymosin beta-4 fragment · TB500	US research-market price boardTissue and thymic peptides	5 of 7 rows in stock10 mg like-for-like comparison8 linked records	Question and boundary This record answers What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access? It does not establish Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	U.S. Food and Drug AdministrationRead the FDA source ↗
TesamorelinEgrifta · TH9507	US research-market price boardGrowth-signaling analogues	4 of 5 rows in stock10 mg like-for-like comparison6 linked records	Question and boundary This record answers What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access? It does not establish Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	U.S. Food and Drug AdministrationCheck the FDA Purple Book product record ↗
Thymosin Alpha-1Thymalfasin · TA1 · Thymosin alpha 1	US research-market price boardTissue and thymic peptides	2 of 3 rows in stock5 mg like-for-like comparison4 linked records	Question and boundary This record answers What did a dated set of public US research seller pages show for nominal size, list price, availability, and evidence access? It does not establish Seller-page observations do not establish identity, purity, quantity, sterility, safety, legality, clinical effect, or suitability for human or veterinary use.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	U.S. Food and Drug AdministrationRead the FDA source ↗
VK2735Viking VK2735 · oral VK2735 · GLP-1/GIP dual agonist	Investigational clinical programObesity and metabolic pipeline	Subcutaneous Phase 3 active; oral Phase 3 plannedViking Therapeutics8 linked records	Question and boundary This record answers Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program? It does not establish Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.	5 matched NCT records0 recruiting · 0 results postedOpen filtered finder →	2026-07-18	ClinicalTrials.govVENTURE injectable Phase 2 study - NCT06068946 ↗
VYLEESI (Bremelanotide)bremelanotide · Vyleesi · PT-141 · NDA 210557	FDA-approved medicineFDA-approved melanocortin medicine	NDA 210557 · FDA-approved prescription drugCosette Pharmaceuticals, Inc.2 linked records	Question and boundary This record answers Which exact product, application, label company, route, and regulatory record did FDA approve? It does not establish Approval applies to the exact medicine and label record. It does not transfer to compounded products, research listings, or similarly named materials, and it does not determine individual suitability.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	National Library of Medicine, DailyMedCurrent VYLEESI prescribing information ↗
WEGOVY (Semaglutide)semaglutide · Wegovy · NDA 215256 · GLP-1 receptor agonist	FDA-approved medicineFDA-approved incretin medicine	NDA 215256 · FDA-approved prescription drugNovo Nordisk Inc.7 linked records	Question and boundary This record answers Which exact product, application, label company, route, and regulatory record did FDA approve? It does not establish Approval applies to the exact medicine and label record. It does not transfer to compounded products, research listings, or similarly named materials, and it does not determine individual suitability.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-18	National Library of Medicine, DailyMedCurrent WEGOVY prescribing information ↗
Zenagamtideamycretin · NNC0487-0111 · AMAZE 7	Investigational clinical programObesity and metabolic pipeline	Phase 3 development underwayNovo Nordisk5 linked records	Question and boundary This record answers Which sponsor, phase, mechanism, route, trial records, and reported findings are attached to this investigational program? It does not establish Investigational status is not approval or retail availability. Separate trials cannot be ranked fairly without matching populations, designs, durations, doses, estimands, and outcome definitions.	24 matched NCT records10 recruiting · 0 results postedOpen filtered finder →	2026-07-20	ClinicalTrials.govAMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414 ↗
ZEPBOUND (Tirzepatide)tirzepatide · Zepbound · LY3298176 · NDA 217806	FDA-approved medicineFDA-approved incretin medicine	NDA 217806 · FDA-approved prescription drugLilly USA, LLC2 linked records	Question and boundary This record answers Which exact product, application, label company, route, and regulatory record did FDA approve? It does not establish Approval applies to the exact medicine and label record. It does not transfer to compounded products, research listings, or similarly named materials, and it does not determine individual suitability.	Not indexed by this snapshotBlank is a scope boundary, not zero.	2026-07-17	National Library of Medicine, DailyMedCurrent ZEPBOUND prescribing information ↗

Data dictionary

Definitions travel with the rows.

The download includes explicit question and boundary fields because an evidence category is only useful when readers can see what it answers and what it cannot establish.

record_id: Stable Peptide Local identifier for the evidence record.
name: Published record name. Medicine rows include the exact brand and active ingredient.
aliases: Alternate names, former names, sponsor codes, application identifiers, or common search forms used for identity resolution.
evidence_category: One of medicine, pipeline, or market. Categories answer different questions and must not be merged into one safety or efficacy scale.
family: Editorial classification used for browsing related records; it is not a therapeutic recommendation.
sponsor_company_or_board: Sponsor for a pipeline program, label company for an approved medicine, or exact-size definition for a research-market board.
current_status: Current status statement carried by the canonical profile on the checked date.
route_or_listing_detail: Route and dosage-form context for medicine and pipeline records, or seller-listing category context for research-market boards.
question_answered: The bounded question this category of record is designed to answer.
interpretation_boundary: The main conclusion the row does not support.
linked_evidence_records: Count of sources or seller observations attached to the canonical profile. This is coverage, not an evidence-quality score.
clinical_trial_records: Count of ClinicalTrials.gov records matched to a pipeline identity by the current 13-program exact-intervention snapshot. Blank for evidence categories outside that snapshot, not zero.
recruiting_clinical_trials: Matched registry records whose overall status was Recruiting at the snapshot timestamp. Registry status does not establish individual eligibility or site access.
posted_trial_results: Matched registry records with a posted ClinicalTrials.gov results module. A blank or zero does not prove that no result exists elsewhere.
clinical_trial_finder_path: Peptide Local trial-finder route filtered to the matched pipeline program when available.
clinical_trial_snapshot_version: Version of the ClinicalTrials.gov snapshot used for identity linkage.
clinical_trial_coverage_scope: Explicit statement describing whether the row is covered by the current 13-program snapshot and how blanks must be interpreted.
checked_date: ISO date when the canonical record and its primary route were last reviewed.
profile_path: Canonical Peptide Local profile path for definitions, context, and additional citations.
source_publisher: Publisher responsible for the primary external record linked by the row.
source_url: Direct HTTPS route to the primary external record without affiliate parameters.

Citation and reuse

Use the landing page as the citation.

Suggested citation: Peptide Local Editorial Desk. “Peptide Local Peptide Evidence and Status Index.” Version 2026-07-24. Peptide Local.

Link this landing page when citing the release so readers retain the data dictionary, category boundaries, correction route, and current version beside the download.

Use the interactive comparison →Search all peptide names and aliases →Read the publication gates →Request a correction or field →